We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Creo Medical Group Plc | CREO | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
36.50 | 36.00 | 36.75 | 36.50 | 36.50 |
Industry Sector |
---|
HEALTH CARE EQUIPMENT & SERVICES |
Top Posts |
---|
Posted at 16/5/2024 09:42 by dr biotech There is some interesting stuff discussed in the investor meet yesterday - if you only have a few mins the Q&A bit was good - not least because half the Qs were mine.Alternative sources of funding could include licensing deals - implies there may be progress on these over the next few month. Also may be some milestones achieved with the robotics partners No real update from NICE or the Lung tumour trial - just have to wait for those. Initial lung trial goal is "do no harm" so bar is quite low. I think the core sales that are up 14% is the total Creo product sales - seems a bit interchangeable what core means - Creo Branded, or just the recent Creo developed. Thought Craig seemed quite confident, he talks well as he should for what he's paid |
Posted at 15/5/2024 09:32 by bootycall @74tom “another cash runway issue” !What do you expect ? How have the best performing shares in the US grown ? By cutting capex or by having a group of investors that understand tech adoption and fund cash shortfalls or rising valuations. This country will not have any meaningful tech companies if we seek to cease innovation just because the regulator was a quarter behind on approval. Having said that i appreciate your attention to detail but rather than fearful speculation, I would prefer to look at revised cash flow forecast and a sober analysis of the position. All too often a Company can be 6 months behind in forward sales guidance and some clown wants to cut the valuation in half. Regarding global sales operations, I have far more sympathy with your arguments. The best margins are always in the USA and using established players in other geographies is a credible strategy for a company of Creos size. Re the management, it is obvious from the new Board appointments that commercial experience is being sought. In the last 15 years Intuitive Surgical has had 14 quarters where it reported negative quarterly sales (mainly 2013/4, 2020 and 2022)..all is not lost :) |
Posted at 15/5/2024 08:03 by dr biotech . Following a strong finish in Q4-23, sales momentum in Creo core products has continued with core revenue in Q1-24 showing a 14% increase over the FY23 quarterly average, and the Company expects to see this accelerate in Q2-24So sales going ok. Some statutory statements about a going concern etc. Doing ok but I was hoping for a bit more. Perhaps they’ll elaborate in the investor meet. |
Posted at 01/5/2024 06:11 by porky9 @Master InvestorAnd you know that because..... Going out on a limb here, as current 35p share price level holding well but i recon i will still be able to get my 15p buy in target later this year before any uplift comes, they wont get BE without more cash is my call. Lets see if i'm proven wrong. From my experience investing in other healthcare stocks where they intend to win major NHS and private health sector deals, irrespective of the possible financial advantages from saved time, it will take significantly longer to win these contracts simply because there is a massive upfront cost and training time and cost to change. Not to mention the gestation period to get a deal from creation of tender process to a decision to actually go with it - snail pace progress for these sorts of decisions is understatement of the year. The albatross around CREOs neck is the cost of sales. The current cash burn to deliver the sales they have is ridiculous. I know they talk about ultimately bringing cash burn down but we are yet to see material proof of that. Otherwise, bloody good tech that will make a difference, that's why this remains on my watch list but im in no hurry, with a £130m mcap whilst losing over £16m a year on £31m of sales and a dwindling cash reserve its currently more than fully priced imo. But good luck to the bulls here |
Posted at 28/4/2024 17:52 by pacsltd Porky, CREO had a raise just over a year ago. So do you think the directors told porkies (excuse the pun) when they suggested at the time:-"The Company is pursuing the Fundraising in order to raise sufficient funds to maintain momentum in the business building on the success of 2022 and the milestones that it has achieved since IPO. The Fundraising is intended to enable the Company to progress into the next stage of the development and commercialisation of its minimally invasive electrosurgical devices, and the Directors expect that the Fundraising will provide the Company with a pathway to being cash flow break even and, ultimately, to profitability as well as give comfort to existing customers, suppliers and partners of increased balance sheet strength. ... The Group continues to progress towards profitability with revenues continuing to grow and the intensive investment product development and launch phase coming to an end. Material reductions in operating costs have contributed to a reduced underlying EBITDA loss for FY22 compared to FY21, which is expected to be in-line with market expectations. Management considers that this combination of strong core product revenue growth and active cost control means that the business is well-positioned to further reduce cash burn in FY23 and remains on track for EBITDA break even during FY25, also in-line with market expectations." So is Porky suggesting that CREO directors got it wrong or misled the institution and private investors a year ago? Just saying. |
Posted at 24/4/2024 13:23 by hatfullofsky peterrr3 - Gulliford is no scientist he was an early investorCraig has over 25 years’ experience in building international businesses from early stage through to significant scale. In January 1999, Craig joined a start-up software and hardware business where, as COO, he was part of a small team that grew the Company both organically and through acquisition, from a loss-making start-up to a profitable business delivering significant shareholder returns and an exit in 2007. If anything he'll be polishing the company for an exit at some point but the pay themselves very handsomley |
Posted at 12/3/2024 12:43 by hatfullofsky Yes I would have expected it to at least have moved to - in development.In this investormeet presentation from 12/09/23 https://www.investor |
Posted at 23/1/2024 08:05 by wan Two companies on Creo investor minds -3 bellwether companies to watch as medtech earnings season begins J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports. Published Jan. 22, 2024 RBC Capital Markets analysts were similarly upbeat, writing about “positive momentum exiting 2023 for both procedure volumes and capital spending” in a note to investors last week. A clearer picture of how the medtech industry fared in the fourth quarter and last year, and how companies expect to perform across 2024, will begin to emerge when J&J and Intuitive report results on Tuesday. Meanwhile, Abbott will report on Wednesday morning. Here, we preview what to look out for in the first week of earnings for the industry: Full story - |
Posted at 12/1/2024 07:45 by wan Intuitive is guiding for growth in procedures, robotic placements, and revenues -Intuitive CEO: Strong robot placements offset bariatric surgery slowdown Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries. Published Jan. 11, 2024 the robotic surgery leader is also seeing strong system placements and growth in general surgeries, CEO Gary Guthart told investors at the J.P. Morgan Healthcare Conference in San Francisco. The company preannounced that overall procedures assisted by its da Vinci robot grew 21% in the fourth quarter, above analysts’ expectations. The momentum prompted Intuitive to forecast an increase of about 13% to 16% in da Vinci procedures worldwide in 2024. In 2023, Intuitive’s da Vinci procedure growth was 22%, as almost 2.29 million surgeries were performed with the systems. The company placed 415 da Vinci robots with customers in the fourth quarter alone, up 12% from the same period a year ago. Preliminary fourth-quarter revenue rose 17% to about $1.93 billion. William Blair analyst Brandon Vazquez said the preliminary fourth-quarter results beat expectations in nearly all categories. “The bottom line is that Intuitive is clearly heading into 2024 with strong momentum,” Vazquez said in a report to clients. Full story - Staying with Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company - The following, also from the above Medtechdive link, provides food for thought - At the J.P. Morgan event, Guthart declined to say whether Intuitive plans to roll out a next-generation multi-port robot in the year ahead, a topic of interest among investors. “The fact that management didn’t comment leaves open the possibility for a launch this year,” J.P. Morgan analyst Robbie Marcus said in a research note after the presentation, pointing out that the executives made clear last year a new robot would not come in 2023. |
Posted at 12/10/2023 10:36 by xxxxxy Creo Medical Group PLC Investor PresentationSource: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions